7.75
前日終値:
$7.70
開ける:
$8.08
24時間の取引高:
6.56M
Relative Volume:
1.31
時価総額:
$2.77B
収益:
$9.68M
当期純損益:
$-250.64M
株価収益率:
-5.5365
EPS:
-1.3998
ネットキャッシュフロー:
$-89.83M
1週間 パフォーマンス:
-0.39%
1か月 パフォーマンス:
+6.46%
6か月 パフォーマンス:
+150.00%
1年 パフォーマンス:
+122.38%
Precigen Inc Stock (PGEN) Company Profile
名前
Precigen Inc
セクター
電話
301-556-9900
住所
20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD
Compare PGEN vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
PGEN
Precigen Inc
|
7.75 | 2.77B | 9.68M | -250.64M | -89.83M | -1.3998 |
|
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
|
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Precigen Inc Stock (PGEN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-15 | アップグレード | JP Morgan | Underweight → Neutral |
| 2024-03-22 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2023-05-23 | 開始されました | JP Morgan | Neutral |
| 2022-11-18 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-02-25 | 開始されました | Stifel | Buy |
| 2021-02-22 | 開始されました | Wells Fargo | Overweight |
| 2021-02-18 | 開始されました | B. Riley Securities | Buy |
| 2020-05-08 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Precigen Inc (PGEN) 最新ニュース
Precigen (PGEN) Gains FDA Platform Backing, Is The Stock Still Cheap? - Yahoo Finance
MRNA, PGEN Stocks Hit Multi-Year Highs – What’s Driving The Momentum Today? - fr.tradingview.com
Precigen (PGEN) Secures FDA Platform Status For AdenoVerse And Future Therapies - Yahoo Finance
B. Riley Securities initiates coverage of Precigen with Buy rating, $12 price target - TradingView
Precigen stock hits 52-week high at 8.05 USD - Investing.com
$Precigen (PGEN.US)$ ready for the next leg higher - Moomoo
PGEN Initiates Coverage On B. Riley Securities -- Rating Set to Buy - GuruFocus
B.Riley initiates Precigen stock coverage with buy on drug launch By Investing.com - Investing.com South Africa
Precigen Initiated at Buy by B. Riley Securities - Moomoo
Form 4 Precigen Inc For: 25 September By Investing.com - Investing.com Canada
B.Riley initiates Precigen stock coverage with buy on drug launch - Investing.com Canada
Form 4 Precigen Inc For: 25 September - Investing.com India
Can PGEN's AdenoVerse Pipeline Create Growth Beyond Papzimeos? - uk.finance.yahoo.com
Vertex Posts Positive Phase II Data on Kidney Disease Drug - Zacks Investment Research
Precigen's AdenoVerse Receives FDA Platform Technology Designation - marketscreener.com
PGEN Looks 47.9% Undervalued on GF Value™ Despite Financial Chal - GuruFocus
FDA grants platform technology status to Precigen’s AdenoVerse - Investing.com
September 2026's Leading Growth Companies With Insider Backing - simplywall.st
Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform - TradingView
Precigen (PGEN) Stock May Be Fully Valued On Its Current Sales Base - Yahoo Finance
Precigen, Inc. (PGEN) Stock Analysis: A 84% Upside Potential Sparks Investor Interest - DirectorsTalk Interviews
Precigen stock hits 52-week high at 7.74 USD By Investing.com - Investing.com Nigeria
Precigen stock hits 52-week high at 7.74 USD - Investing.com
Precigen Gains 43% in 3 Months: Is It an Indication to Buy the Stock? - finance.yahoo.com
Exploring 3 High Growth Tech Stocks In The US Market - simplywall.st
Can Papzimeos Drive Precigen's Growth Through the Rest of 2026? - Yahoo Finance
Precigen Insider Sold Shares Worth $1,376,400, According to a Recent SEC Filing - Yahoo Finance
Trade Alert: Independent Director Of Precigen Jeffrey Kindler Has Sold Stock - simplywall.st
Precigen (PGEN) Director Jeffrey Kindler Sells 185,000 Shares - GuruFocus
Precigen director Jeffrey Kindler sells $1.38m in stock By Investing.com - Investing.com Australia
Precigen (PGEN) director sells 185K shares in one day - Stock Titan
Does Reliance On Papzimeos Skew Precigen’s (PGEN) Risk Profile Or Validate Its Focused Strategy? - Yahoo Finance
Is Precigen (PGEN) Undervalued After Reaching Quarterly Profitability? - sahmcapital.com
Precigen director Jeffrey Kindler sells $1.38m in stock - Investing.com
Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen - Yahoo Finance
Precigen (PGEN) director plans 185,000-share 2026 sale - Stock Titan
Precigen COO Rutul Shah sells $375,000 in shares By Investing.com - Investing.com South Africa
Precigen CCO Phil Tennant sells $593,745 in stock By Investing.com - Investing.com Nigeria
Precigen Insider Sold Shares Worth $375,000, According to a Recent SEC Filing - marketscreener.com
Precigen (PGEN) insider lines up another stock sale after four recent trades - Stock Titan
Precigen (NASDAQ: PGEN) officer to sell 79,166 shares in 2026 - Stock Titan
Precigen's Strong Second Quarter Signals Significant Growth, Validates AdenoVerse Platform; PRGN-2009 Advances in HPV-Driven Cancers - Investing News Network
3 Growth Companies With High Insider Ownership And 55% Earnings Growth - Sahm
Precigen (PGEN) officer targets $259,935 insider stock sale - Stock Titan
Precigen (NASDAQ:PGEN) Trading Down 3.6%Here's Why - MarketBeat
$Precigen (PGEN.US)$ keep it up! - Moomoo
Precigen (NASDAQ:PGEN) Hits New 12-Month HighTime to Buy? - MarketBeat
Precigen stock hits 52-week high at 7.33 USD By Investing.com - Investing.com Australia
Reasons Why Investors Should Consider Betting on PGEN Stock - TradingView
Precigen (PGEN) Stock: Ends Up by 6.30% at $7.17 in the Latest Session; Key Range: Support at $6.81 and Resistance at $7.53 Frame the Range under the Current SnapshotPut Spread Alert - vinanet.vn
Stock Traders Buy Large Volume of Precigen Call Options (NASDAQ:PGEN) - MarketBeat
Precigen Inc (PGEN) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):